Influence of gastric inhibitory polypeptide on pentagastrin-stimulated gastric acid secretion in patients with type 2 diabetes and healthy controls

Table 1 Characteristics of the participants (mean±SE)    

Parameter	Healthy	Patients with	Significance
(unit)	controls	type 2 diabetes	(P-value)
Sex (female/male)	2/6	2/6	1.0
Age (years)	46 ± 6	54 ± 10	0.07
Body mass index (kg/m2)	28.9 ± 5.3	30.5 ± 2.2	0.43
Waist-to-hip ratio (cm/cm)	0.97 ± 0.08	1.00 ± 0.05	0.40
Blood pressure
Systolic (mmHg)	118 ± 13	138 ± 21	0.044
Diastolic (mmHg)	79 ± 10	92 ± 10	0.026
HbA1c (%)1	6.0 ± 0.5	8.3 ± 2.2	0.013
Diabetes duration (years)	-	9 ± 4	-
Total-cholesterol (mg/dL)	223 ± 52	210 ± 35	0.57
HDL-cholesterol (mg/dL)	49 ± 22	34 ± 14	0.15
LDL-cholesterol (mg/dL)	145 ± 37	164 ± 31	0.32
Triglycerides (mg/dL)	161 ± 110	167 ± 92	0.90
Creatinine (mg/dL)	0.86 ± 0.13	1.05 ± 0.29	0.12

Statistics: ANOVA or χ² test.

¹Normal range: < 6.5

Table 2 Gastric acid and chloride secretion in patients with type 2 diabetes and healthy controls (mean±SE)

Experimental period:	Basal	Pentagastrin	Hyperglycemia	Placebo	GIP low	GIP high	Significance
Time (min):	(-90)	(-45 to -30)	(-15 to 0)	(45 to 60)	(105 to 120)	(165 to 180)	(P -value)
Healthy controls
H+ -secretion [mmol/15 min]	1.9 ± 0.4	6.2 ± 0.9	7.2 ± 0.7	8.1 ± 1.1	7.9 ± 1.0	6.5 ± 0.5	< 0.001
Cl- -secretion [mmol/15 min]	1.9 ± 0.4	7.9 ± 1.0	9.0 ± 0.8	9.9 ± 1.3	9.6 ± 1.2	8.0 ± 0.7	< 0.001
Patients with type 2 diabetes
H+ -secretion [mmol/15 min]	1.6 ± 0.4	8.3 ± 1.7	8.3 ± 1.7	9.5 ± 1.8	8.6 ± 1.7	8.2 ± 1.6	< 0.01
Cl- -secretion [mmol/15 min]	1.6 ± 0.4	11.1 ± 1.4	11.7 ± 2.1	12.5 ± 2.1	11.8 ± 1.7	11.4 ± 1.5	<0.001

Statistics: ANOVA